CHICAGO — Administering modified FOLFIRINOX chemotherapy before chemoradiation, surgery and adjuvant chemotherapy improved survival outcomes of patients with locally advanced rectal cancer, according to results of the PRODIGE 23 trial.“The most important point of PRODIGE 23 is the overall survival benefit,” Thierry Conroy, MD, of the department of medical oncology at Institut de